Association of AKI With mortality and complications in hospitalized patients with cirrhosis

Justin M. Belcher, Guadalupe Garcia‐Tsao, Arun J. Sanyal, Harjit Bhogal, Joseph K. Lim, Naheed Ansari, Steven G. Coca, Chirag R. Parikh, for the TRIBE‐AKI Consortium – 27 March 2012 – Acute kidney injury (AKI) is a common and devastating complication in patients with cirrhosis. However, the definitions of AKI employed in studies involving patients with cirrhosis have not been standardized, lack sensitivity, and are often limited to narrow clinical settings.

Increasing the recipient benefit/donor risk ratio by lowering the graft size requirement for living donor liver transplantation

See Ching Chan, Sheung Tat Fan, Kenneth S. H. Chok, William W. Sharr, Wing Chiu Dai, James Y. Y. Fung, Kwok Yin Chan, Dharmesh J. Balsarkar, Chung Mau Lo – 27 March 2012 – In living donor liver transplantation (LDLT), a right liver graft is larger than a left liver graft and hence leads to better recipient survival. However, in comparison with donor left hepatectomy, donor right hepatectomy carries a higher donor risk.

Outcomes of liver transplantation for patients with alagille syndrome: The studies of pediatric liver transplantation experience

Binita M. Kamath, Wanrong Yin, Heather Miller, Ravinder Anand, Elizabeth B. Rand, Estella Alonso, John Bucuvalas, for Studies of Pediatric Liver Transplantation – 27 March 2012 – Alagille syndrome (ALGS) is a multisystem disorder that manifests as childhood cholestasis. Reports of liver transplantation (LT) for patients with ALGS have come largely from single centers, which have reported survival rates of 57% to 79%. The aim of this study was to determine LT outcomes for patients with ALGS.

Predicting the discharge status after liver transplantation at a single center: A new approach for a new era

Dympna M. Kelly, Renee Bennett, Nancy Brown, Judy McCoy, Derek Boerner, Changhong Yu, Bijan Eghtesad, Wael Barsoum, John J. Fung, Michael W. Kattan – 27 March 2012 – The aim of this study was to develop a tool for preoperatively predicting the need of a patient to attend an extended care facility after orthotopic liver transplantation (OLT).

Cost‐effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C

Calogero Cammà, Salvatore Petta, Marco Enea, Raffaele Bruno, Fabrizio Bronte, Vincenza Capursi, Americo Cicchetti, Giorgio L. Colombo, Vito Di Marco, Antonio Gasbarrini, Antonio Craxì, on behalf of the WEF Study Group – 27 March 2012 – Randomized controlled trials (RCTs) show that triple therapy (TT) with peginterferon alpha, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon‐ribavirin dual therapy (DT) in the treatment of previously untreated patients with genotype 1 (G1) chronic hepatitis C (CHC).

Subscribe to